<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366802">
  <stage>Registered</stage>
  <submitdate>28/07/2014</submitdate>
  <approvaldate>25/09/2014</approvaldate>
  <actrnumber>ACTRN12614001035617</actrnumber>
  <trial_identification>
    <studytitle>Does an innovative method of sequencing, known as next generation sequencing (NGS), applied for normal embryo selection in infertile patients improve pregnancy rate in fresh transfer?</studytitle>
    <scientifictitle>In patients with fertility problems, does preimplantation genetic diagnosis, compared to group without preimplantation genetic diagnosis, improve pregnancy rate? </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>infertility </healthcondition>
    <healthcondition>embryo aneuploidy</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Involves patient's biopsied embryos genetic analysis. Choice of the embryos for transfer was based on the preimplantation genetic diagnosis using next generation sequencing (PGD NGS) results.
Duration: 12 hours of analysis
Frequency: Once in this investigation</interventions>
    <comparator>ICSI with preimplantation genetic diagnosis (PGD) vs standard treatment (ICSI without PGD). In control group selection of embryos for transfer was based on microscopic morphology analysis and rate of divisions analysis.</comparator>
    <control>Active</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>pregnancy rate (as ultrasound fetal heartbeat detection)</outcome>
      <timepoint>on 6 weeks and 1-3 days post embryo transfer</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>implantation rate (by transvaginal ultrasound)</outcome>
      <timepoint>5 weeks and 3 days +/- 2 days post embryo transfer</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>miscarriage rate (ultrasound)</outcome>
      <timepoint>up to 12 weeks post embryo transfer</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Patients undergoing intracytoplasmic sperm injection (ICSI) in Invicta Fertility and Reproductive Centre s. z o.o. in time frame from 08.2013 to 01.2014
2. At least two previous implantation failures
</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>38</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Patients with endometriosis or adenomiosis
2. Patients with problems related to endometrium thickness</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Diagnosis</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/08/2013</anticipatedstartdate>
    <actualstartdate>1/08/2013</actualstartdate>
    <anticipatedenddate>1/07/2014</anticipatedenddate>
    <actualenddate>1/07/2014</actualenddate>
    <samplesize>98</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Poland</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Invicta s. z o.o.</primarysponsorname>
    <primarysponsoraddress>ul. Trzy lipy 3, 80-172 Gdansk, Poland</primarysponsoraddress>
    <primarysponsorcountry>Poland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Invicta s. z o.o.</fundingname>
      <fundingaddress>ul. Trzy lipy 3, 80-172, Gdansk</fundingaddress>
      <fundingcountry>Poland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Objective: To determine the usefulness of semiconductor-based next generation sequencing (NGS) for cleavage-stage preimplantation genetic diagnosis (PGD) of aneuploidy.
Setting: A private centers for reproductive medicine.
Patient(s): Patients underwent day-3 embryo biopsy with PGD and fresh cycle transfer. Additionaly, 53 patients, matched according to age, anti-mullerian hormone (AMH) levels, antral follicles count (AFC) and infertility duration were selected to serve as controls.
Intervention(s): Choice of the embryos for transfer was based on the PGD NGS results.
Main Outcome Measure(s): Clinical pregnancy rate (PR) per embryo transfer was our primary outcome. Secondary outcomes were the implantation rate, and miscarriage rate. 
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes>We have been performing preimplantation genetic diagnosis (PGD) for many years now (using FISH method). As we decided to introduce a new and more reliable tool for PGD - next generation sequencing (NGS) we submitted appropriate application to Ethics Committee before enrolment of first patient. We didn't receive Committee consent but a notification that such agreement is not necessary in case of routine research like PGD. However, after our insistence we received a consent retrospectively in which the Committee explained that their had agreed although their agreement was not necessary in this case.</publicnotes>
    <ethicscommitee>
      <ethicname>Komisja Bioetyczna przy Okregowej Izbie Lekarskiej</ethicname>
      <ethicaddress>ul. Sniadeckich 33, 80-204 Gdansk, Poland</ethicaddress>
      <ethicapprovaldate>20/05/2014</ethicapprovaldate>
      <hrec>11/14</hrec>
      <ethicsubmitdate>6/05/2014</ethicsubmitdate>
      <ethiccountry>Poland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Krzysztof Lukaszuk</name>
      <address>Invicta Reproductive and Fertility Centres
ul. Trzy lipy 3, 80-172 Gdansk</address>
      <phone>+48 58 58 58 810</phone>
      <fax />
      <email>sekretariatlukaszuk@invicta.pl</email>
      <country>Poland</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Judyta Zabielska</name>
      <address>Invicta Reproductive and Fertility Centres
ul. Trzy lipy 3, 80-172, Gdansk</address>
      <phone>+48 516 829 691</phone>
      <fax />
      <email>judytazabielska@gmail.com</email>
      <country>Poland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Judyta Zabielska</name>
      <address>Invicta Reproductive and Fertility Centres
ul. Trzy lipy 3, 80-172, Gdansk</address>
      <phone>+48 516 829 691</phone>
      <fax />
      <email>judytazabielska@gmail.com</email>
      <country>Poland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Judyta Zabielska</name>
      <address>ul. Trzy lipy 3, 80-172, Gdansk</address>
      <phone>+48 516 829 691</phone>
      <fax />
      <email>judytazabielska@gmail.com</email>
      <country>Poland</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>